Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

European Journal of Cancer

Volumn 35, Issue 1, 1999, Pages 54-59

  Van Cutsem, E ^a   Cunningham, D ^b   Ten Bokkel Huinink, W W ^c   Punt, C J A ^d   Alexopoulos, C G ^e   Dirix, L ^f   Symann, M ^g   Blijham, G H ^h   Cholet, P ⁱ   Fillet, G ^j   Van Groeningen, C ^k   Vannetzel, J M ^l   Levi, F ^m   Panagos, G ⁿ   Unger, C ^o   Wils, J ^p   Cote, C ^q   Blanc, C ^q   Herait P ^q   Bleiberg, H ^r  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e EVANGELISMOS HOSPITAL   (Greece)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ Jean Perrin Centre   (France)

^j CHU Saint Tilman   (Belgium)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l Clinique Hartman   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ Anargini Hospital   (Greece)

^o UNIVERSITY OF FREIBURG   (Germany)

^p LAURENTIUS HOSPITAL   (Netherlands)

^q SANOFI   (France)

^r JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

5 FU resistant; Chemotherapy; Colon cancer; CPT 11; Irinotecan

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033053920     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00353-0     Document Type: Article

References (26)

1. Cunningham D., Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer. 29A:1993;2077-2079.
2. Glimelius B., Pahlman L., Graf W., et al. for the Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer - a randomized trial. J Clin Oncol. 10:1992;904-911.
3. Scheithauer W., Rosen H., Kornek G-V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 306:1993;752-755.
4. Piedbois P., Buyse M., Rustum Y., et al. for the Advanced Colorectal Cancer Meta-Analysis Project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer - evidence in terms of response rate. J Clin Oncol. 10:1992;896-903.
5. Moore TD, Cole KE, Christian MC, Arbuck S. Trials of investigational drugs in colorectal cancer. In Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, eds. Cancer of the Colon, Rectum and Anus. New York, NY, McGraw-Hill, 1995, 919-931.
6. Arbuck S.G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 63:1989;1036-1044.
7. Weh H.J., Wilke H.J., Dierlamm J., et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU), 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol. 5:1994;233-237.
8. Creemers G.J., Lund B., Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 20:1994;73-96.
9. Armand J.P., Ducreux M., Mahjoubi M., et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 31A:1995;1283-1287.
10. Conti J.A., Kemeny N.E., Saltz L.B., et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 14:1996;709-715.
11. Rothenberg M.L., Eckardt J.R., Kuhn J.G., et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 14:1996;1128-1135.
12. Rougier P., Bugat E., Douillard J., et al. Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:1997;251-260.
13. Fleming T.R. One sample multiple testing procedure for phase II clinical trials. Biometrics. 38:1982;143-151.
14. Ahlgren J.D., Trocki O., Gullo J.J., et al. Protracted infusion of 5-FU with weekly low dose cisplatin as second line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest. 9:1991;27-33.
15. Sobrero A., Nobile M.T., Gugliemi A., et al. Phase II study of 5-fluorouracil plus leucovorin and interferon 2β in advanced colorectal cancer. Eur J Cancer. 28A:1992;850-852.
16. Findlay M., Hill A., Cunningham D., et al. Protracted venous infusion of 5-fluorouracil and interferon alpha in advanced and refractory colorectal cancer. Ann Oncol. 5:1994;239-243.
17. Conti J.A., Kemeny N.E., Saltz L.B., Andre A.M., Grossano D.D., Bertino J.R. Continuous infusion fluorouracil/leucovorin and bolus mitomycin C as a salvage regimen for patients with advanced colorectal cancer. Cancer. 75:1995;769-774.
18. Valone F.H., Kohler M., Fisher K., et al. A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone. NCI Monograph. 5:1987;175-177.
19. Palmieri G., Gridelli C., Airoma G., et al. Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. J Chemother. 3:1991;55-60.
20. Cascinu S., Fedeli A., Luzi Fedeli S., Catalano G. Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. J Chemother. 4:1992;46-49.
21. Levi F., Perpoint B., Garufi C., et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5 day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 9:1993;1280-1284.
22. Machover D., Diaz-Rubio E., de Gramont A., et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 7:1996;95-98.
23. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 33:1997;214-219.
24. Graf W., Påhlman L., Bergström R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer. 70:1994;559-563.
25. Glimelius B., Hoffman K., Graf W., Pahlman L., Sjoden P.O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer. 73:1994;556-562.
26. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 12:1994;14-20.